ETF Inflow Update: IVW, AXP, BSX, PGR
Written by Emily J. Thompson, Senior Investment Analyst
Source: NASDAQ.COM
Stock Performance Overview
- 52-Week Range: IVW's stock has a low point of $79.31 and a high point of $116.39 over the past year, with the most recent trade recorded at $114.79.
- Technical Analysis: The comparison of the current share price to the 200-day moving average is highlighted as a useful technique for investors.
Exchange-Traded Funds (ETFs) Insights
- Trading Mechanism: ETFs function similarly to stocks, where investors buy and sell "units" instead of shares. These units can be created or destroyed based on investor demand.
- Monitoring Changes: Weekly tracking of changes in shares outstanding helps identify ETFs with significant inflows (new units created) or outflows (old units destroyed), which can influence the underlying assets of the ETFs.
Additional Information
- Author's Perspective: The views expressed in the article are solely those of the author and do not necessarily represent the opinions of Nasdaq, Inc.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BSX is 125.74 USD with a low forecast of 112.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
20 Buy
0 Hold
0 Sell
Strong Buy
Current: 91.290
Low
112.00
Averages
125.74
High
140.00
Current: 91.290
Low
112.00
Averages
125.74
High
140.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
